Lakefront Biotherapeutics (LKFT) Finished Goods (2020 - 2023)

Lakefront Biotherapeutics (LKFT) has 4 years of Finished Goods data on file, last reported at $6.6 million in Q4 2023.

• Finished Goods for Q4 2023 came in at $6.6 million, down 19.99% year-over-year; the trailing twelve-month figure through Dec 2023 was $6.6 million (down 19.99% YoY), and the FY2023 annual result was $6.6 million, down 19.99% from the prior year.
• Finished Goods eased to $6.6 million in Q4 2023 per LKFT's latest filing, from $8.2 million in the prior quarter.
• Over five years, Finished Goods peaked at $8.2 million in Q4 2022 and troughed at $42922.4 in Q4 2020.
• A 4-year average of $5.1 million and a median of $6.1 million in 2023 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2021 and 2023: Finished Goods jumped 12804.92% in 2021, then declined 19.99% in 2023.
• A 4-year view of Finished Goods shows it stood at $42922.4 in 2020, then soared by 12804.92% to $5.5 million in 2021, then soared by 48.51% to $8.2 million in 2022, then declined by 19.99% to $6.6 million in 2023.
• Business Quant data shows LKFT's Finished Goods at $6.6 million in Q4 2023, $8.2 million in Q4 2022, and $5.5 million in Q4 2021.